---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-006012"
form_type: "8-K"
ticker: "NKTX"
cik: "0001787400"
company_name: "Nkarta, Inc."
filed_at: "2022-04-22T23:59:59+00:00"
generated_at: "2026-06-26T05:25:12.845276+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.2
confidence: "high"
source: SEC EDGAR
---

# Nkarta to host April 25 conference call to discuss Phase 1 data for NKX101 and NKX019

## Summary
- Conference call scheduled for April 25, 2022 at 8:00 a.m. ET to review preliminary clinical data.
- NKX101 and NKX019 are engineered NK cell therapy candidates in ongoing Phase 1 trials.
- Leading investigators from the two clinical trials will join management for the discussion.
- Webcast and accompanying slides available on Nkarta’s website with replay for ~4 weeks.

## SEC filing metadata
- accession: 0000950170-22-006012
- form_type: 8-K
- ticker: NKTX
- cik: 0001787400
- company_name: Nkarta, Inc.
- filed_at: 2022-04-22T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.2
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787400/000095017022006012/0000950170-22-006012-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787400/000095017022006012/nktx-20220422.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-006012
- JSON: https://secwatch.observer/filing/0000950170-22-006012.json
- Plain text: https://secwatch.observer/filing/0000950170-22-006012.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.